Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical United States Business Strategies

Eyeing Both A Partnership And An IPO, Aragon Takes $42M Series C

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

A well-connected fund that invests on behalf of a group of high-net-worth investors provides cash to complete a Phase II trial on prostate cancer drug ARN-509, and bring a breast cancer drug into the clinic.

Table

View full table

Advertisement

Related Content

Pink Sheet Pink Sheet Pink Sheet Pink Sheet Pink Sheet Pink Sheet Pink Sheet Scrip Scrip

Topics

Related Companies

Advertisement
Tags:
BioPharmaceutical United States Business Strategies
UsernamePublicRestriction

Register

PS073843

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By